Organization Profile

You just read:

Sophiris Announces First Patients Dosed in the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia

News provided by

Sophiris Bio, Inc.

Oct 28, 2013, 16:05 ET